<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413335</url>
  </required_header>
  <id_info>
    <org_study_id>0508000532</org_study_id>
    <nct_id>NCT00413335</nct_id>
  </id_info>
  <brief_title>Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth</brief_title>
  <official_title>Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether treatment of children and adolescents with
      Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin
      sensitivity and glucose tolerance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Impaired Glucose Tolerance (IGT) is a prelude to diabetes, which is increasing in prevalence
      in obese children and adolescents with marked obesity. This condition tends to progress to
      Type 2 Diabetes Mellitus (T2DM) at an alarmingly rapid tempo. The increased prevalence of
      childhood and adolescent obesity and greater risk of IGT, and progression to diabetes, in
      this population set the stage for a series of studies aimed at understanding the metabolic
      phenotype and natural history of pre-diabetes in obese youth. The investigators found that
      obese children and adolescents with IGT are characterized by marked insulin resistance
      related to altered lipid partitioning, favoring lipid deposition in the visceral and
      intramyocellular compartment. Furthermore, the investigators found an impairment of the acute
      insulin response in these youngsters. Follow-up revealed a rapid deterioration from IGT to
      frank diabetes. Based on these studies, there is a strong rationale for changing the balance
      between visceral and subcutaneous fat and muscle lipid content in a more favorable pattern in
      order to improve insulin sensitivity.

      The primary objective of this study is to determine, in a group of ethnically diverse
      children and adolescents with IGT, whether treatment with rosiglitazone leads to improvements
      in insulin sensitivity and glucose tolerance. Secondary objectives are to determine whether
      rosiglitazone is safe and well tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline in Whole-body Insulin Sensitivity</measure>
    <time_frame>4 months</time_frame>
    <description>This describes the percent changes in insulin sensitivity. Insulin sensitivity was expressed as whole body insulin sensitivity index (WBISI) which is based on the values of insulin (microunits per milliliter) and glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values.The formula is: WBISI=10.000/square root of (fasting glucose x fasting insulin)x(mean glucose x mean insulin).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change in Visceral-to-subcutaneous Abdominal Fat</measure>
    <time_frame>4 months</time_frame>
    <description>This describes the percent changes of the ratio between visceral and subcutaneous abdominal fat.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Who Converted Impaired Glucose Tolerance (IGT) to Normal Glucose Tolerance (NGT)</measure>
    <time_frame>4 months</time_frame>
    <description>This refers to the number of subjects that converted from IGT to NGT. NGT is defined as fasting glucose lower than 100 mg/dl and 2 hours glucose lower than 140 mg/dl. IGT is defined as 2 hours glucose higher than 140 mg/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline in Hepatic Fat Fraction (HFF)</measure>
    <time_frame>4 months</time_frame>
    <description>It refers to the percent changes of hepatic fat content.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Adiponectin</measure>
    <time_frame>4 months</time_frame>
    <description>This refers to the changes of adiponectin levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Obesity</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>2mg to begin then 4mg, twice daily for 4 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subject receives placebo.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general health

          -  Aged 10 to 18 yrs (females: Tanner stage II-V;and males:testes size&gt;6ml)

          -  IGT based on 2-hr plasma glucose&gt;140mg/dl and &lt;200mg/dl during an OGTT.

        Exclusion Criteria:

          -  Baseline creatinine&gt;1.0mg

          -  AST and ALT&gt;2.5 ULN

          -  Anemia (Hct&lt;30)

          -  Pregnancy (females must have a negative urine pregnancy test during the study)

          -  Cardiac or pulmonary or other significant chronic illness

          -  Plans to increase the frequency or intensity of a regular exercise program

          -  Psychiatric disorder or substance abuse of anorexic agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonia Caprio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine Department of Pediatric Endocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <results_first_submitted>November 7, 2012</results_first_submitted>
  <results_first_submitted_qc>March 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2013</results_first_posted>
  <last_update_submitted>July 15, 2013</last_update_submitted>
  <last_update_submitted_qc>July 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Sonia Caprio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Childhood and Adolescent Obesity</keyword>
  <keyword>Metabolic phenotype</keyword>
  <keyword>Impaired Glucose Tolerance</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Insulin Sensitivity</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Abdominal fat partitioning</keyword>
  <keyword>Impaired Glucose Tolerance (IGT)</keyword>
  <keyword>Type 2 Diabetes Mellitus (T2DM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from a multi-ethnic cohort of obese children and adolescents drawn from the Pediatric Obesity Clinic at Yale-New Haven Hospital.</recruitment_details>
      <pre_assignment_details>Obese children and adolescents with positive risk factors for Type 2 Diabetes (T2DM) were screened by using a standard oral glucose tolerance test (OCTT).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Arm (Rosiglitazone)</title>
          <description>Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
Rosiglitazone : 2mg to begin then 4mg, twice daily for 4 months</description>
        </group>
        <group group_id="P2">
          <title>Inactive Arm (Placebo)</title>
          <description>Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
Placebo : Subject receives placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Arm (Rosiglitazone)</title>
          <description>Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
Rosiglitazone : 2mg to begin then 4mg, twice daily for 4 months</description>
        </group>
        <group group_id="B2">
          <title>Inactive Arm (Placebo)</title>
          <description>Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
Placebo : Subject receives placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="1.6"/>
                    <measurement group_id="B2" value="13.9" spread="2.0"/>
                    <measurement group_id="B3" value="13.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline in Whole-body Insulin Sensitivity</title>
        <description>This describes the percent changes in insulin sensitivity. Insulin sensitivity was expressed as whole body insulin sensitivity index (WBISI) which is based on the values of insulin (microunits per milliliter) and glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values.The formula is: WBISI=10.000/square root of (fasting glucose x fasting insulin)x(mean glucose x mean insulin).</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Arm (Rosiglitazone)</title>
            <description>Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
Rosiglitazone : 2mg to begin then 4mg, twice daily for 4 months</description>
          </group>
          <group group_id="O2">
            <title>Inactive Arm (Placebo)</title>
            <description>Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
Placebo : Subject receives placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Whole-body Insulin Sensitivity</title>
          <description>This describes the percent changes in insulin sensitivity. Insulin sensitivity was expressed as whole body insulin sensitivity index (WBISI) which is based on the values of insulin (microunits per milliliter) and glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values.The formula is: WBISI=10.000/square root of (fasting glucose x fasting insulin)x(mean glucose x mean insulin).</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4" spread="77.0"/>
                    <measurement group_id="O2" value="63.1" spread="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in Visceral-to-subcutaneous Abdominal Fat</title>
        <description>This describes the percent changes of the ratio between visceral and subcutaneous abdominal fat.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Arm (Rosiglitazone)</title>
            <description>Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
Rosiglitazone : 2mg to begin then 4mg, twice daily for 4 months</description>
          </group>
          <group group_id="O2">
            <title>Inactive Arm (Placebo)</title>
            <description>Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
Placebo : Subject receives placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Visceral-to-subcutaneous Abdominal Fat</title>
          <description>This describes the percent changes of the ratio between visceral and subcutaneous abdominal fat.</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="23.1"/>
                    <measurement group_id="O2" value="8.9" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Converted Impaired Glucose Tolerance (IGT) to Normal Glucose Tolerance (NGT)</title>
        <description>This refers to the number of subjects that converted from IGT to NGT. NGT is defined as fasting glucose lower than 100 mg/dl and 2 hours glucose lower than 140 mg/dl. IGT is defined as 2 hours glucose higher than 140 mg/dl.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Arm (Rosiglitazone)</title>
            <description>Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
Rosiglitazone : 2mg to begin then 4mg, twice daily for 4 months</description>
          </group>
          <group group_id="O2">
            <title>Inactive Arm (Placebo)</title>
            <description>Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
Placebo : Subject receives placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Converted Impaired Glucose Tolerance (IGT) to Normal Glucose Tolerance (NGT)</title>
          <description>This refers to the number of subjects that converted from IGT to NGT. NGT is defined as fasting glucose lower than 100 mg/dl and 2 hours glucose lower than 140 mg/dl. IGT is defined as 2 hours glucose higher than 140 mg/dl.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Adiponectin</title>
        <description>This refers to the changes of adiponectin levels.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Arm (Rosiglitazone)</title>
            <description>Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
Rosiglitazone : 2mg to begin then 4mg, twice daily for 4 months</description>
          </group>
          <group group_id="O2">
            <title>Inactive Arm (Placebo)</title>
            <description>Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
Placebo : Subject receives placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Adiponectin</title>
          <description>This refers to the changes of adiponectin levels.</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" spread="78.2"/>
                    <measurement group_id="O2" value="19.8" spread="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline in Hepatic Fat Fraction (HFF)</title>
        <description>It refers to the percent changes of hepatic fat content.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Arm (Rosiglitazone)</title>
            <description>Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
Rosiglitazone : 2mg to begin then 4mg, twice daily for 4 months</description>
          </group>
          <group group_id="O2">
            <title>Inactive Arm (Placebo)</title>
            <description>Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
Placebo : Subject receives placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Hepatic Fat Fraction (HFF)</title>
          <description>It refers to the percent changes of hepatic fat content.</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="107"/>
                    <measurement group_id="O2" value="81" spread="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Arm (Rosiglitazone)</title>
          <description>Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
Rosiglitazone : 2mg to begin then 4mg, twice daily for 4 months</description>
        </group>
        <group group_id="E2">
          <title>Inactive Arm (Placebo)</title>
          <description>Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
Placebo : Subject receives placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sonia Caprio, Principal Investigator</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-785-5692</phone>
      <email>Sonia.Caprio@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

